Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-05
2011-04-05
Haq, Shafiqul (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007920, C435S007930, C435S007940, C435S070210, C436S512000, C436S518000, C436S547000, C436S548000, C530S388200, C530S388240, C530S388250, C530S389200, C530S389300, C530S391100
Reexamination Certificate
active
07919255
ABSTRACT:
A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.
REFERENCES:
patent: 2003/0219734 (2003-11-01), Buechler
patent: WO 01/14885 (2001-03-01), None
Prickett et al., 2001. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochemical and Biophysical Research Communications 286: 513-517.
Yasoda et al., 2000. C-type natriuretic peptide (CNP) as a novel skeletal growth factor: skeletal overgrowth of the transgenic mice that overexpress CNP specifically in cartilage. Journal of Bone and Mineral Research 15 (Suppl. 1): S243, Abstract SA050.
Chusho et al., “Dwarfism and Early Death in Mice Lacking C-Type Natriuretic Peptide,”Proc. Natl. Acad. Sci. USA, 98(7):4016-4021, Mar. 27, 2001.
Desai Meena, “Growth Disorders,”Med. J. Armed Forces Ind., 59(4):278-282, 2003.
Hama et al., “A Monoclonal Antibody to C-Type Natriuretic Peptide—Preparation and Application to Radioimmunoassay and Neutralization Experiment,”J. Endocrinology, 141:473-479, 1994, Odd pages only.
Harlow at al., “Immunizations,”Antibodies: A Laboratory Manual, Cold Springs Harbor Laboratory, 53-137, 1988.
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science, 246:1275-1281, Dec. 8, 1989.
Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature, 256:(5517): 495-497, Aug. 7, 1975.
Prickett et al., “Identification of Amino-Terminal Pro-C-Type Natriuretic Peptide in Human Plasma,”Biochemical and Biophysical Research Communications, 286(3):513-517, 2001, Odd pages only.
Rasat et al., “IGF-1 and IGFBP-3 Screening for Disorders of Growth Hormone Secretion,”NZ Med. J.,109: 156-159, May 10, 1996.
Stepan et al., “Expression of C-Type Natriuretic Peptide in Human Placenta and Myometrium in Normal Pregnancies and Pregnancies Complicated by Intrauterine Growth Retardation,”Fetal Diagn. Ther., 17:37-41, 2002, Odd pages only.
Tanner et al., “Clinical Longitudinal Standards for Height and Height Velocity for North American Children,”J. Pediatrics, 107(3):317-329, Sep. 1985, Odd only.
Prickett et al. Amino-Terminal proCNP: A Putative Marker of Cartilage Activity in Postnatal Growth. Pediatric Research vol. 58, No. 2, pp. 334-340, 2005.
Examination Report dated May 29, 2007 issued by the Intellectual Property Office of New Zealand in related NZ Application No. 553281.
Examination Report dated Jul. 14, 2008 issued by the European Patent Office in related EP Application No. 04 748 820.0, listing references D1-D10 cited by the European Examiner.
Stepan, H. et al., “Detection of C-type natriuretic peptide in fetal circulation,” Journal of Perinatal Medicine, 28(2):118-121 (2000).
Vargas, S.J. et al., “Effects of Atrial Natriuretic Factor on Cyclic Nucleotides, Bone Resorption, Collagen and Deoxyribonucleic Acid Synthesis, and Prostaglandin E2 Production in Fetal Rat Bone Cultures,” Endocrinology, Baltimore, MD, US, 125(5):2527-2531 (1989).
De Feo, M.L. et al, “Natriuretic Hormone Receptors and Actions on Bone Endothelial Cells,” Endocrinology, Baltimore, MD, US, 133(4):1759-1766 (1993).
Mericq, V. et al., “Regulation of Fetal Rat Bone Growth by C-Type Natriuretic Peptide and cGMP,” Pediatric Research, Williams and Wilkins, Baltimore, MD, US, 47(2):189-193 (2000).
Examination Report dated Nov. 17, 2008 issued by the Intellectual Property Office of New Zealand in related NZ Application No. 553281.
Examination Report dated Feb. 4, 2009 issued by the European Patent Office in related EP Application No. 04 748 820.0.
Espiner Eric Arnold
Nicholls Michael Gary
Prickett Timothy Charles Ramsey
Richards Arthur Mark
Yandle Timothy Grant
Grun James L
Haq Shafiqul
Haynes and Boone LLP
Otago Innovation Limited
LandOfFree
Assessment of skeletal growth using measurements of NT-CNP... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessment of skeletal growth using measurements of NT-CNP..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessment of skeletal growth using measurements of NT-CNP... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2709427